LEIDEN, NETHERLANDS--(MARKET WIRE)--Mar 3, 2008 -- Leiden, The Netherlands, 3 March 2008 - Dutch biotechnology company Crucell N.V. today announced that it has entered into an exclusive vaccine development agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE - News).
Under the terms of the agreement, Crucell will be responsible for the development and manufacture of certain components of a vaccine for use by Wyeth in clinical studies. The development activities will take place in Crucell's dedicated vaccine manufacturing facilities in Bern, Switzerland. Wyeth will be responsible for the clinical development of the vaccine. Financial details were not disclosed.
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biotechnology company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Portugal, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).
For further information please contact:
Barbara Mulder Oya Yavuz
Director Corporate Communications Director Investor Relations
Tel: +31-(0)71-519 7346 Tel: +31-(0)71-519 7064
Copyright © Hugin AS 2008. All rights reserved.
Source: Crucell N.V.